Clinical Trial Goal
To find out if talquetamab is safe and works well to treat multiple myeloma that has relapsed or is refractory after receiving CAR T-cell therapy
You may be able to join this trial if you:
- Are 18 years old or older
- Have multiple myeloma that has relapsed or is refractory
- Have been treated with all of the following (your doctor can tell you this):
- CAR T-cell therapy that targets BCMA, in the last 1-3 months
- Immunomodulatory drugs (IMiD's). Some examples include:
- Lenalidomide
- Pomalidomide
- Thalidomide
- Monoclonal antibody that targets CD38
- Protease inhibitors
- Do not have any of the following:
- Plasma cell leukemia
- POEMS syndrome
- Waldenstrom's macroglobulinemia
- Have not been treated with the following:
- A drug that targets GRPRC5D
- T-cell therapy. Some examples include:
- Bi-specific T-cell engager (BiTE) therapy
- Have not received an allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 6 months
- Have not received an autologous (your own cells) BMT in the last 3 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Talquetamab is a monoclonal antibody that targets CD37 on certain cells.
You’ll get:
You’ll get:
- Talquetamab – Given as a shot under your skin. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved talquetamab.
Locations
Sponsors
lead: Memorial Sloan Kettering Cancer Center, collaborator: Janssen Pharmaceuticals
